Skip to main content
Premium Trial:

Request an Annual Quote

Avant Completes Acquisitions of Amarantus, Theranostics Health

NEW YORK (GenomeWeb) – Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health.

In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus' research-use-only assays for multiple sclerosis and Alzheimer's disease with Avant's upcoming microarray-based ovarian cancer diagnostic OvaDx.

Under the terms of that arrangement, Avant acquired all outstanding shares of Amarantus in exchange for 80 million shares of Avant stock, with additional shares to be issued upon certain undisclosed milestones.

Two months later, Avant and Amarantus announced that they had signed a letter of intent to add privately held Theranostics to the merger, which would give the combined company a CLIA lab to support its pipeline of diagnostics, as well as Theranostics' TheraLink assay for identifying known drug targets of breast cancer therapeutics.

Under the terms of the deal, Avant acquired the assets and operations of Theranostics in exchange for 25 million shares of its stock, which was trading at $.32 per share on the OTC Bulletin Board on Thursday morning.

The stock issued under the two transactions are subject to an 18-month lockup, with certain exceptions.

"The closing of these acquisitions marks a pivotal moment for Avant," Avant President and CEO Gregg Linn said in a statement. "We have simultaneously expanded our product pipeline … [and] have acquired the appropriate CLIA/CAP infrastructure required to commercialize our pipeline while also gaining access to a growing pharma services revenue stream with the very same sales, distribution channels, commercial relationships, and overall scientific focus required for successful introduction of our additional proprietary assets to the pharma services market."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.